Ligand Pharmaceuticals LGND Proceeds From Sale Of Short Term Investments
Proceeds From Sale Of Short Term Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's proceeds from sale of short term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's proceeds from sale of short term investments?
- Ligand Pharmaceuticals (LGND) reported proceeds from sale of short term investments of $1.3M in Q1 2026.
- How has Ligand Pharmaceuticals's proceeds from sale of short term investments changed year-over-year?
- Ligand Pharmaceuticals's proceeds from sale of short term investments decreased by 96.6% year-over-year, from $38.41M to $1.3M.
- What is the long-term trend for Ligand Pharmaceuticals's proceeds from sale of short term investments?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's proceeds from sale of short term investments has grown at a 0.9% compound annual growth rate (CAGR), from $154.23M to $159.58M.